Michel Orsinger, former chairman of Global Orthopedics Johnson & Johnson, has joined the Advisory Board of Lima Corporate, a company based in Udine, Italy.
Michel Orsinger Joins Lima Corporate Advisory Board

According to the March 1, 2017 news release, “Michel Orsinger held the position of Worldwide Chairman DePuy Synthes Companies at Johnson & Johnson (J&J) from 2012 to 2015. He was also a member of J&J’s Global Management Team. Michel Orsinger joined Johnson & Johnson following the sale of Synthes Inc. for $20 billion, the largest acquisition ever realized by Johnson & Johnson to date. Subsequently, Michel Orsinger established the worldwide largest and most comprehensive orthopedic company. Prior to his leadership role at J&J, Mr. Orsinger was COO and CEO of Synthes Inc for eight years, and spent eleven years with Novartis. Today, Michel Orsinger is an investor as well as board member of several start-up companies and an advisor to EQT. Moreover, he joined the Board of Takeda in 2016, the largest Japanese and Asian pharmaceutical company. Michel Orsinger is also active in philanthropic initiatives, including volunteer work in Africa, supporting surgeons and local health care professionals in establishing adequate education programs to improve patient care. He holds a Business Administration Degree from the University of St. Gallen (Switzerland) and has attended Management Programs at the Harvard Business School and at INSEAD.”
“I am very happy that Michel as another high quality veteran of our industry has decided to join the Advisory Board” said Luigi Ferrari, CEO of Lima Corporate. “Michel’s expertise in the orthopaedic as well as medical device industry and track record of growing companies will accelerate our development.”
Orsinger told OTW, “My healthcare and medical technology industry experience gained over the many past years, combined with my global leadership experience in reputable companies, will be of added value to Lima. Also my previous and current Board positions in start-ups and in a larger health care company are of relevance.”
“First of all I want to meet the team and learn as much as I can about the business, including their challenges and opportunities. Subsequently, I will want to make contributions in best supporting management, especially related to patient and customer focus, innovation and business development, geographical expansion and talent! I am very excited to have the opportunity to work with a group of very committed multicultural people, to support the dynamic and impressive growth of Lima, and last but not least to continue to contribute to patient care.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.